| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2011PLoSO...623828E |
| P356 | DOI | 10.1371/JOURNAL.PONE.0023828 |
| P932 | PMC publication ID | 3157473 |
| P698 | PubMed publication ID | 21858228 |
| P5875 | ResearchGate publication ID | 51587036 |
| P2093 | author name string | Tina Dalianis | |
| Kalle Andreasson | |||
| Karin Tegerstedt | |||
| Mathilda Eriksson | |||
| Torbjörn Ramqvist | |||
| Kajsa Lundberg | |||
| Joachim Weidmann | |||
| P2860 | cites work | Circulating antibody to prostate antigen in patients with prostate cancer | Q72731744 |
| Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation | Q73470451 | ||
| Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer | Q33361082 | ||
| CD4+ and CD8+ T cells can act separately in tumour rejection after immunization with murine pneumotropic virus chimeric Her2/neu virus-like particles | Q33640368 | ||
| Self-assembly of purified polyomavirus capsid protein VP1. | Q34162517 | ||
| Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases | Q34627305 | ||
| Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model | Q35891225 | ||
| Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer | Q36589857 | ||
| A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. | Q36626087 | ||
| Activities of polyomavirus large-T-antigen proteins expressed by mutant genes | Q36918983 | ||
| Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic | Q37353496 | ||
| Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors | Q39931841 | ||
| High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals | Q39936356 | ||
| Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor | Q40176278 | ||
| Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer. | Q40377659 | ||
| Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. | Q40400486 | ||
| Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. | Q40491652 | ||
| Role of androgens in prostatic cancer. | Q40562425 | ||
| Murine pneumotropic virus VP1 virus-like particles (VLPs) bind to several cell types independent of sialic acid residues and do not serologically cross react with murine polyomavirus VP1 VLPs. | Q40612744 | ||
| T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes | Q40784739 | ||
| Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection | Q40948891 | ||
| Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer | Q41067119 | ||
| A controlled trial of leuprolide with and without flutamide in prostatic carcinoma | Q41261975 | ||
| The influence of hormonal therapy on survival of men with advanced prostatic cancer. | Q41457056 | ||
| Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP | Q41648841 | ||
| A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors | Q43831558 | ||
| Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. | Q44412471 | ||
| The risk of dying of prostate cancer in patients with clinically localized disease | Q44469353 | ||
| Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials | Q44634881 | ||
| Assembly of recombinant rotavirus proteins into virus-like particles and assessment of vaccine potential | Q45775698 | ||
| Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA. | Q45880565 | ||
| A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer | Q46577596 | ||
| The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. | Q53890793 | ||
| Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide | Q57100266 | ||
| Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer | Q64377598 | ||
| Analysis of fixation effects on immunohistochemical localization of prostatic specific antigen in human prostate | Q68969190 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Murine polyomavirus | Q18974626 |
| P304 | page(s) | e23828 | |
| P577 | publication date | 2011-08-17 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor | |
| P478 | volume | 6 |
| Q38839675 | Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer |
| Q38285854 | Antigen delivery by virus-like particles for immunotherapeutic vaccination. |
| Q38172045 | Bioengineering virus-like particles as vaccines |
| Q42250611 | Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants. |
| Q35775195 | Construction of polyomavirus-derived pseudotype virus-like particles displaying a functionally active neutralizing antibody against hepatitis B virus surface antigen |
| Q34455275 | Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses |
| Q38025665 | Immunotherapy for polyomaviruses: opportunities and challenges |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q38152475 | VLPs and particle strategies for cancer vaccines |
| Q45324534 | Virus like particles as a platform for cancer vaccine development. |
| Q62128249 | Virus-like particle-based vaccines for animal viral infections |
| Q38088523 | Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development |
| Q38019283 | Virus-like particles: the new frontier of vaccines for animal viral infections. |
| Q39012245 | Yeast as an expression system for producing virus-like particles: what factors do we need to consider? |
Search more.